United Therapeutics jumps 12% on a patent win it hasn't filed with the SEC
United Therapeutics rose 12.55% on a court ruling, Rogers 10.73% on investor-day targets and FormFactor 9.59% on analyst interest. None of the three has an 8-K behind the move.
Seoul — United Therapeutics (UTHR) rose 12.55% to $541.89 on Sept. 30 in U.S. trading, Rogers (ROG) gained 10.73% to $152.99 and FormFactor (FORM) added 9.59% to $149.31. The cause is clearest for United Therapeutics, where a court ruling came out; Rogers rose on company targets and FormFactor on an analyst's rating. The S&P 500 fell 0.25%, the Nasdaq Composite rose 0.24% and the Russell 2000, an index of small caps, fell 0.39%. (As of 7:36 p.m. KST, Oct. 1)
| Stock | Why it rose | Nature of the news | Evidence | What to watch |
|---|---|---|---|---|
| United Therapeutics | Delaware court ruled Liquidia's Yutrepia infringes its patent | Substance, one-off | Reports only | Whether an 8-K follows; appeal |
| Rogers | Investor Day set 2030 revenue target of $1.5 billion | Expectation | Reports only | Whether quarterly results back the targets |
| FormFactor | Analyst buy rating, chip-equipment sentiment | Expectation | Reports only | Next-day trading value; insider-sale filings |
United Therapeutics rose 12.55% on a patent win over Liquidia (no 8-K filed)
The stock rose because United Therapeutics won its patent case against rival Liquidia (LQDA). The company's Sept. 30 press release, carried by Yahoo, said it prevailed in the litigation, and TIKR reported that a Delaware court ruled Yutrepia infringes its patent. Yahoo reported that Liquidia shares then fell 57% in a day.
However, the only recent filings on SEC EDGAR are Form 4 insider-trading reports; no 8-K (current report) about the ruling appears over the past seven days. The evidence is the company's press release and media reports. The stock was up 11.6% over two days and 10.7% over five, after trading mostly in the $470s to $510s for weeks. Dollar volume was about $1.79 billion, or 7.7% of the roughly $23.2 billion market cap.
A ruling is documented substance, but how much it changes sales cannot be told from the data. A Yahoo headline on Liquidia says an appeal could decide whether its shares rebound. To judge whether the gain holds, watch whether the company confirms the ruling in an 8-K, and whether Liquidia appeals and what the court orders.
Rogers rose 10.73% on investor-day targets, not on results
Rogers rose after its Sept. 30 Investor Day, where, according to Yahoo, it set a 2030 revenue target of $1.5 billion; scanx.trade reported an FY28 EPS target of $5.50–$6.50 and revenue of up to $1.1 billion. The slide deck was published by the company, per Seeking Alpha. No SEC filings appeared in the past seven days.
This is a plan rather than a booked result, so we treat it as expectation. The stock went from $138.17 to $152.99, up 21.3% since Aug. 26, for a market cap of about $2.73 billion. Dollar volume was about $167 million.
How firm the targets are will show in upcoming quarterly results. Watch whether sales and earnings track the stated path and whether the company repeats the figures in an 8-K or earnings release.
FormFactor rose 9.59% on a buy rating and chip-gear sentiment (no company announcement)
FormFactor rose on an analyst's buy rating. Yahoo reported the semiconductor test-equipment maker received a fresh buy rating from a Wall Street analyst and tied the morning gain to Deutsche Bank. The company itself announced only its participation in a CEO investor summit, with no price-relevant filing or contract.
The stock had already run: from $102.94 on Sept. 14 to $149.31, about 45%, with 14.0% in the last two days alone. Some outlets mentioned a CEO share sale, but no such filing appears in EDGAR's list. An analyst opinion is not a confirmed fact, so we treat it as expectation.
To judge whether it lasts, watch whether trading value stays near the day's $328.8 million next session and whether any insider sale shows up on a Form 4.